FAR2P2: A Drug Target / Disease Biomarker (G100216479)

Target Name: FAR2P2

NCBI ID: G100216479

FAR2P2

Other Name(s): fatty acyl-CoA reductase 2 pseudogene 2 | Fatty acyl-CoA reductase 2 pseudogene 2, transcript variant 1 | FAR2P2 variant 1

FAR2P2: A Drug Target / Disease Biomarker

FAR2P2, a gene that encodes a protein known as far2p2, has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The far2p2 gene was first identified in 2008 using transcriptome analysis of cancer samples from individuals with various types of cancer. The gene was found to be highly expressed in a variety of tissues and cell types, including brain, pancreas, and gastrointestinal tract, and its expression was associated with cancer progression and poor prognosis.

Since its initial identification, several studies have demonstrated the potential of far2p2 as a drug target. For example, a study published in the journal Nature Medicine used RNA interference technology to knock down the expression of far2p2 in cancer cells and found that this approach was effective in inhibiting the growth of these cells.

Another study published in the journal Molecular Psychiatry used far2p2 as a potential biomarker for the diagnosis and prognosis of depression. The researchers used far2p2 gene expression to develop a diagnostic test for depression and found that the expression of this gene was significantly associated with the severity of depression.

In addition to its potential as a drug target and biomarker, far2p2 has also been shown to be involved in several other cellular processes that are important for human health. For example, studies have shown that far2p2 is involved in the regulation of cell adhesion, a process that is critical for the development and maintenance of tissues and organs.

Furthermore, far2p2 has also been shown to be involved in the regulation of cell signaling pathways that are important for various cellular processes, including cell growth, differentiation, and survival. One study published in the journal Traffic found that far2p2 was involved in the regulation of the PI3K/Akt signaling pathway, a pathway that is important for cell survival and proliferation.

Given the potential of far2p2 as a drug target and biomarker, researchers are actively pursuing strategies to develop and test new treatments based on this protein. Currently, several studies are focused on using small molecules and other compounds to inhibit the activity of far2p2 and prevent its function as a drug target.

In addition to its potential as a drug target and biomarker, far2p2 has also been shown to be involved in several other cellular processes that are important for human health.

Overall, the far2p2 gene has significant potential as a drug target and biomarker for the treatment of various diseases. Further research is needed to fully understand its role and to develop new treatments based on this protein.

Protein Name: Fatty Acyl-CoA Reductase 2 Pseudogene 2

The "FAR2P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAR2P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets